ATE434762T1 - Biologischer marker für entzündung - Google Patents

Biologischer marker für entzündung

Info

Publication number
ATE434762T1
ATE434762T1 AT05812529T AT05812529T ATE434762T1 AT E434762 T1 ATE434762 T1 AT E434762T1 AT 05812529 T AT05812529 T AT 05812529T AT 05812529 T AT05812529 T AT 05812529T AT E434762 T1 ATE434762 T1 AT E434762T1
Authority
AT
Austria
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Application number
AT05812529T
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Lea Madi
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE434762(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of ATE434762T1 publication Critical patent/ATE434762T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05812529T 2004-12-02 2005-11-30 Biologischer marker für entzündung ATE434762T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001279 WO2006059327A1 (en) 2004-12-02 2005-11-30 A biological marker for inflammation

Publications (1)

Publication Number Publication Date
ATE434762T1 true ATE434762T1 (de) 2009-07-15

Family

ID=35708899

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05812529T ATE434762T1 (de) 2004-12-02 2005-11-30 Biologischer marker für entzündung
AT05813139T ATE402739T1 (de) 2004-12-02 2005-11-30 Behandlung von entzündungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05813139T ATE402739T1 (de) 2004-12-02 2005-11-30 Behandlung von entzündungen

Country Status (13)

Country Link
US (3) US20080056992A1 (de)
EP (2) EP1817589B1 (de)
JP (2) JP4842964B2 (de)
KR (2) KR20070100261A (de)
AT (2) ATE434762T1 (de)
AU (2) AU2005310873B2 (de)
BR (2) BRPI0518777A2 (de)
CA (2) CA2586773C (de)
DE (2) DE602005015135D1 (de)
DK (1) DK1817079T3 (de)
ES (2) ES2327435T3 (de)
MX (2) MX2007006500A (de)
WO (2) WO2006059327A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
US20080300213A1 (en) 2005-11-30 2008-12-04 Pnina Fishman Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
US9102698B2 (en) 2007-03-14 2015-08-11 Can-Fite Biopharma Ltd. Process for the synthesis of IB-MECA
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
US20130045943A1 (en) * 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
EP2583972B1 (de) * 2010-06-18 2018-04-18 Hayashibara Co., Ltd. Therapeutikum für entzündungskrankheiten mit adenosin-n1-oxid als wirkstoff
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181351A4 (de) 1984-05-09 1989-06-21 Univ Australian Verfahren zur modulierung der immunologischen antwort.
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
WO2004036215A2 (en) * 2002-10-21 2004-04-29 Can-Fite Biopharma Ltd. Diagnostic markers for therapeutic treatment
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
ATE371191T1 (de) * 2002-10-22 2007-09-15 Can Fite Biopharma Ltd Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
WO2004045627A1 (en) * 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
UY28391A1 (es) 2003-06-25 2004-12-31 Elan Pharm Inc Metodos y composiciones para tratar artritis reumatoide
EP1699459B1 (de) 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
AU2005310874A1 (en) 2006-06-08
CA2586774A1 (en) 2006-06-08
AU2005310873B2 (en) 2008-11-27
JP2008521883A (ja) 2008-06-26
DE602005008639D1 (de) 2008-09-11
US20080056992A1 (en) 2008-03-06
JP2008522182A (ja) 2008-06-26
CA2586773A1 (en) 2006-06-08
WO2006059328A1 (en) 2006-06-08
ES2327435T3 (es) 2009-10-29
EP1817589B1 (de) 2009-06-24
DE602005015135D1 (de) 2009-08-06
MX2007006500A (es) 2007-07-13
EP1817589A1 (de) 2007-08-15
MX2007006501A (es) 2007-07-13
EP1817079A1 (de) 2007-08-15
ATE402739T1 (de) 2008-08-15
WO2006059327A1 (en) 2006-06-08
AU2005310874B2 (en) 2008-11-27
JP4842964B2 (ja) 2011-12-21
BRPI0518777A2 (pt) 2008-12-09
CA2586773C (en) 2018-03-27
EP1817079B1 (de) 2008-07-30
AU2005310873A1 (en) 2006-06-08
US20100256084A1 (en) 2010-10-07
KR20070090222A (ko) 2007-09-05
DK1817079T3 (da) 2008-11-17
KR20070100261A (ko) 2007-10-10
US20130345163A1 (en) 2013-12-26
BRPI0518795A2 (pt) 2008-12-09
US8541182B2 (en) 2013-09-24
ES2309817T3 (es) 2008-12-16

Similar Documents

Publication Publication Date Title
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2007127749A3 (en) Predicting mortality and detecting severe disease
WO2008041953A3 (en) Dengue diagnosis and treatment
WO2005103281A3 (en) Platelet biomarkers for the detection of disease
DE602007006672D1 (de) Testverfahren und kit zur vorhersage des implantationserfolgs bei unterstützter befruchtung
ATE434762T1 (de) Biologischer marker für entzündung
EP1427810A4 (de) Verfahren und quantifizierungsassay zur bestimmung des c-kit/scf/pakt-status
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
WO2015048336A3 (en) Markers for amyotrophic lateral sclerosis (als) and presymptomatic alzhimer's disease (psad)
EP3185013A3 (de) Biomarker zur bestimmung eines allotransplantattoleranten phänotyps
CY1112423T1 (el) Αναλυτικη συσκευη μικροεπεξεργαστη μιας χρησης
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
BRPI0713380A2 (pt) Métodos para determinar in vitro a quantidade de ácidos nucleicos nucleares em pelo menos uma célula, e para diagnosticar e/ou prognosticar câncer em um indivíduo humano ou animal
WO2007044622A8 (en) Use of mif and mif pathway agonists
BRPI0512948A (pt) biomarcadores de mal de alzheimer
WO2011113942A3 (en) Method for predicting the responsiveness to chemotherapy
WO2005118872A3 (en) Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor
DK1393078T3 (da) Fremgangsmåder til diagnosticering in vitro eller til overvågning af en sygdom involverende en inflammatorisk reaktion
EA201001340A1 (ru) Улучшенный аналитический способ для определения латентного гепатита с, его применения и соответствующий диагностический набор
Fujihara The mechanism of serum cell-free DNA release in postmortem subjects and novel markers to estimate the postmortem intervals
DK1576187T3 (da) Fremgangsmåde til bestemmelse af mængden af cirkulerende DNA i plasma samt påvisning af cancer
RU2004122769A (ru) Способ определения формы лепры
UA60095U (ru) Способ прогнозирования осложнения заживления перелома

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties